Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA approval. Litigation continues with Aurobindo.
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024 FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Amicus Therapeutics Stock Sees RS Rating Improve To 74 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Amicus Therapeutics Stock Sees Improved Relative Strength Rating In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on.
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease The FDA has approved Amicus Therapeutics' (
NASDAQ: FOLD ) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease.
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81.
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier.
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday.
